Webinar: De-risking biosimilar programs

Webinar | De-risking biosimilar programs: Tackling biosimilarity challenges

Wednesday, October 14, 2026

Session 1: 10 a.m. CET | 2:30 p.m. IST | 5 p.m. HKT  

Session 2: 8 a.m. PST |  11 a.m. EST | 5 p.m. CET

Regulatory focus on interchangeability is making early alignment of protein quality attributes with the originator's profile more critical than ever. This webinar explores how a highly efficient, data-driven approach to cell line development can help you meet these demands without slowing down your timeline.

Using a case study of a biosimilar to a blockbuster biologic, we demonstrate how a comprehensive cell line development approach combines automated clone screening, advanced data modeling, and an early focus on critical quality attributes (CQAs). See how simultaneous process and media optimization, guided by a design of experiments (DoE) approach, helped increase titer and optimize the N-glycan profile — and how several rounds of fine-tuning helped identify a lead clone and ensure a process ready for scale-up.

What You Will Learn:

Learn how advanced clone screening and DoE can accelerate biosimilar cell line development.
Discover strategies for controlling CQAS to support regulatory comparability.
Explore a real-world case study for de-risking development toward commercialization.

Clear form data

Please Complete the Form

First Name *

Last Name *

Email *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Register

Christiane Hartmann

Scientist Operations

Christiane Hartmann, PhD, is a scientist with more than eight years of experience in the biotechnology and pharmaceutical industries. She works at Sartorius as a scientist specializing in customer-focused cell line development projects. In this role, she is the scientific lead within project teams, conducting data evaluations and engaging in in-depth scientific discussions with clients.  